Table 1

HiFi-specific prognostic signature and relapse free survival

Gene
(median exp)
Univariate HR
High versus Low
(95% CI)
Univariate p valueMultivariate HR
High versus Low
(95% CI)
Multivariate p valueTotal cases
(relapse)
High exp
(relapse)
Low exp
(relapse)
FGL2
(5.497)
0.568
(0.282 to 1.142)
0.1130.374
(0.166 to 0.840)
0.01774 (33)37 (13)37 (20)
PSME1
(7.384)
0.541
(0.269 to 1.089)
0.0850.364
(0.153 to 0.868)
0.02374 (33)37 (13)37 (20)
SP110
(6.082)
0.498
(0.245 to 1.014)
0.0550.339
(0.148 to 0.775)
0.01074 (33)37 (12)37 (21)
WARS
(6.510)
0.387
(0.187 to 0.801)
0.0100.319
(0.145 to 0.705)
0.00574 (33)37 (33)37 (20)
CCND2
(9.464)
0.574
(0.285 to 1.155)
0.1200.438
(0.204 to 0.939)
0.03474 (33)37 (13)37 (20)
CCND3
(7.715)
0.513
(0.252 to 1.043)
0.0650.414
(0.192 to 0.893)
0.02574 (33)37 (12)37 (21)
PNPT1
(2.560)
0.312
(0.148 to 0.657)
0.0020.265
(0.118 to 0.593)
0.00174 (33)37 (10)37 (23)
Dataset
(median sig)
Univariate HR
High versus
CI)
Univariate p valueMultivariate HR
High versus Low
(95% CI)
Multivariate p valueTotal cases
(relapse)
High sig
(relapse)
Low sig
(relapse)
Discovery
(6.482)
0.395
(0.191 to 0.816)
0.0120.218
(0.087 to 0.544)
0.00174 (33)36 (10)38 (23)
Validation
(9.137)
0.123
(0.027 to 0.550)
0.0060.093
(0.019 to 0.466)
0.00452 (14)26 (2)26 (12)
  • Median gene expression values were used to dichotomise the HiFi patients into high and low expression groups in Discovery cohort. Multivariate Cox regression analysis adjusted for age, sex, pT stage, tumour location, tumour differentiation grade, tumour subtype (mucinous/non-mucinous), lymphovascular invasion and the number of lymph nodes with relapse free survival as the outcome variable.

  • Median signature expression was used to dichotomise the HiFi patients in each cohort into high and low expression groups in both Discovery and Validation cohorts. For the discovery cohort, the multivariate Cox regression analysis adjusted for age, sex, pT stage, tumour location, tumour differentiation grade, tumour subtype (mucinous/non-mucinous), lymphovascular invasion and the number of lymph nodes with relapse free survival as the outcome variable. For the validation cohort, the multivariate Cox regression analysis adjusted for age, sex, TNM stage and tumour location with relapse free survival as the outcome variable.

  • HiFi, high fibroblast.